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Role of 5′TG3′-interacting factors (TGIFs) in Vorinostat (HDAC
inhibitor)-mediated corneal fibrosis inhibition
Ajay Sharma,1,3 Nishant R. Sinha,3 Saad Siddiqui,3 Rajiv R. Mohan1,2,3
Harry S. Truman Memorial Veteran Hospital, Columbia, MO; 2Mason Eye Institute, School of Medicine, Columbia, MO;
Veterinary Medicine and Surgery, University of Missouri, Columbia, MO

1
3

Purpose: We have previously reported that vorinostat, an FDA-approved, clinically used histone deacetylase (HDAC)
inhibitor, attenuates corneal fibrosis in vivo in rabbits by blocking transforming growth factor β (TGFβ). The 5′TG3′interacting factors (TGIFs) are transcriptional repressors of TGFβ1 signaling via the Smad pathway. The present study
was designed to explore the expression of TGIFs in human corneal fibroblasts and to investigate their role in mediating
the antifibrotic effect of vorinostat.
Methods: Human corneal fibroblast cultures were generated from donor corneas. RNA isolation, cDNA preparation, and
PCR were performed to detect the presence of TGIF1 and TGIF2 transcripts. The cultures were exposed to vorinostat
(2.5 µM) to test its effect on TGIF mRNA and protein levels using qPCR and immunoblotting. Myofibroblast formation
was induced with TGFβ1 (5 ng/ml) treatment under serum-free conditions. The changes in fibrosis parameters were
quantified by measuring fibrosis marker α-smooth muscle actin (αSMA) mRNA and protein levels with qPCR, immunostaining, and immunoblotting. Smad2/3/4 and TGIF knockdowns were performed using pre-validated RNAi/siRNAs
and a commercially available transfection reagent.
Results: Human corneal fibroblasts showed the expression of TGIF1 and TGIF2. Vorinostat (2.5 µM) caused a 2.8–
3.3-fold increase in TGIF1 and TGIF2 mRNA levels and a 1.4–1.8-fold increase in TGIF1 and TGIF2 protein levels.
Vorinostat treatment also caused a significant increase in acetylhistone H3 and acetylhistone H4. Vorinostat-induced
increases in TGIF1 and TGIF2 were accompanied by a concurrent decrease in corneal fibrosis, as indicated by a decrease
in αSMA mRNA by 83±7.7% and protein levels by 97±5%. The RNAi-mediated knockdown of Smad2, Smad3, and
Smad4 markedly attenuated TGFβ1-evoked transdifferentiation of fibroblasts to myofibroblasts. The siRNA-mediated
knockdown of TGIF1 and TGIF2 neutralized vorinostat-evoked decreases in αSMA mRNA by 31%–45% and protein
levels by 12%–23%.
Conclusions: Human corneal fibroblasts demonstrate the expression of TGIF1 and TGIF2 transcription factors. These
transcriptional repressors are critical, at least partially, in mediating the antifibrotic effect of vorinostat in the cornea.

signaling in mediated TGFβ-induced transdifferentiation of
human fibroblasts to myofibroblasts [8,9].

Corneal scarring is a third leading cause of global
blindness, often caused due to injury, trauma, and/or infection to the eye [1]. No potent and safe therapeutic agents
are currently available to treat corneal fibrosis, and corneal
transplantation remains the only option to restore vision. The
epithelial-stromal interaction in the cornea plays an important
role in corneal wound healing following injury. To counter
damage caused by trauma or injury, corneal epithelial and
stromal cells release a wide variety of cytokines and growth
factors [2-4]. Out of many cytokines, transforming growth
factor β (TGFβ) has been identified as a key inducer of
corneal fibrosis [5,6]. TGFβ has been shown to activate both
Smad-dependent and Smad-independent pathways, such as
the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling [5-8]. However,
very limited studies have shown the direct evidence of Smad

Numerous literature reports suggest that HDAC inhibitors can cause repression of TGFβ-induced profibrotic genes,
including collagen (Col) type 1 and smooth muscle actin
(αSMA) [10,11]. Additionally, it is also reported that HDAC
inhibitors attenuate TGFβ-driven epithelial-to-mesenchymal
transition (EMT) [12,13]. Recently, our laboratory demonstrated that epigenetic modulation of corneal wound healing
by histone deacetylase (HDAC) inhibitors is an innovative approach to effectively treat corneal fibrosis without
significant complications or side effects [14,15]. We found
that HDAC inhibitors are selective and potent inhibitors of
corneal fibrosis in rabbits in vivo, and that they attenuate
TGFβ-induced profibrotic expression of genes in canine,
equine, and human corneal fibroblasts in vitro [14-17].
Although several HDAC inhibitors are being investigated
for their antifibrotic effects, vorinostat is the only HDAC
inhibitor that is already FDA-approved for humans, and is
currently in clinical use to treat cutaneous T-cell lymphoma.

Correspondence to: Rajiv R. Mohan, University of Missouri, 1600
E. Rollins Rd, Columbia, MO 65211; Phone: (573) 884-1449; FAX:
(573) 884-4100, email: mohanr@health.missouri.edu
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Previous studies from our laboratory have demonstrated that
vorinostat can inhibit TGFβ-mediated transdifferentiation
of cultured corneal fibroblasts to myofibroblasts and laser
surgery-induced corneal scarring in rabbits [15-17]. Unlike
other antifibrotic agents, vorinostat is relatively non-toxic
and does not affect the viability or proliferation of corneal
fibroblasts [15-17]. However, the mechanism mediating the
antifibrotic effect of vorinostat in the cornea is not yet known.
The TGFβ–Smad pathway is modulated by a wide variety
of Smad co-repressors, including c-Ski, SnoN, Smads6,
Smad7, and 5′TG3′-interacting factors (TGIFs) [18-20].
Recently, TGIFs have gained more attention because of their
role in cell proliferation and cell differentiation [21,22]. TGIFs
are members of the three amino acid loop extension (TALE)
class of homeodomain proteins and consist of two closely
related transcription factors, TGIF1 and TGIF2. Both TGIF1
and TGIF2 can cause repression of TGFβ1-activated genes by
direct competition with the coactivator p300/CBP for Smad2
interactions [23]. TGIF1 expression has been detected in few
adult tissues, whereas TGIF2 was ubiquitously expressed
in several adult human tissues [24-27]. The expression and
role of TGIFs in the adult cornea is still unknown. In the
present study, we tested the hypothesis that TGIF1 and TGIF2
are expressed in human corneal fibroblasts, and that these
proteins are involved in mediating the anti-fibrotic effects of
vorinostat in the cornea using an in vitro model. Our results
demonstrate that human corneal fibroblasts express TGIF1
and TGIF2 transcription factors, and that upregulation of
these transcriptional repressors contributes, at least partially,
to the antifibrotic effect of vorinostat in the cornea.
METHODS
Human corneal fibroblast and myofibroblast cultures:
Primary corneal fibroblast cultures were generated from
donor human corneas procured from an eye bank (Heartland
Eye Bank, Kansas City, MO). Based on the slit lamp, specular
microscopy, physical examination, and donor medical record
data provided by the eye bank, it was ensured that only
healthy and disease-free corneas were used in the present
study. Corneal tissues were washed with a sterile cell culture
medium, and the epithelium and endothelium were removed
by gentle scraping with a #15 scalpel blade. The corneal
stroma was cut into small sections, placed on a culture dish,
and incubated in a humidified 5% CO2 incubator at 37 °C
in minimum essential medium (MEM) supplemented with
10% fetal bovine serum for two to three weeks. The primary
human corneal fibroblasts harvested from these corneal
buttons were seeded in six-well plates in MEM supplemented
with 10% fetal bovine serum and allowed to reach 60%–70%
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confluence. To generate myofibroblast cultures, the fibroblasts were seeded using MEM containing 10% fetal bovine
serum, switched to serum-free medium containing TGFβ1
(5 ng/ml) after 12 h, and incubated for 5 days. The cultures
were fed with fresh serum-free TGFβ1-containing medium
every 24 h.
Vorinostat, siRNA and RNAi treatment: A 10 mM stock solution of vorinostat (Cayman Chemical Company, Ann Arbor,
MI) was prepared in dimethylsulfoxide (DMSO) and diluted
with MEM to achieve a final concentration of 2.5 µM in the
culture medium. The equivalent amount of DMSO (0.5 µl in
2 ml culture medium) served as controls. For the knockdown
of TGIF1 and TGIF2 gene expression, prevalidated siRNA
(Ambion Life technologies, Grand Island, NY) were used
at a 30 nM concentration (Table 1). For the knockdown of
Smad2/3/4, the prevalidated RNA interference (RNAi)
oiligos (Table 1) were cloned into a pcDNA 6.2 miR RNAi
expression vector under the control of Pol II promoter (Life
Technologies, Grand Island, NY). The siRNA and RNAi
plasmid transfections were performed using the commercially available transfection reagent lipofectamine3000 (Life
technologies corporation, Grand Island, NY) as per the
manufacturer’s instructions. Briefly, a transfection solution
was prepared by adding 10 µl lipofectamine3000 in 200 µl
of optiMEM medium to the appropriate amounts of siRNA/
RNAi plasmid in 200 µl of opitiMEM. The mixture was incubated for 5 min at room temperature. The above transfection
mixture was added to the human corneal fibroblasts in 1 ml
of a serum-free culture medium.
RNA extraction and cDNA synthesis: Total RNA from cells
was extracted with an RNeasy kit (Qiagen, Valencia, CA) and
reverse transcribed to cDNA following the vendor’s instructions (Promega, Madison, WI). PCR was performed for the
detection of TGIF1 and TGIF2. A 50 µl reaction mixture
containing 2 µl cDNA, 2 µl forward (200 nM) and 2 µl
reverse (200 nM) primer, 0.2 mM of each deoxynucleotide
triphosphates (dNTP), and 1.25 U of Taq polymerase was
run one cycle at 95 °C for 3 min, then 40 cycles of 95 °C
for 30 s, followed by 55 °C for 30 s and 72 °C for 60 s, using
a thermocycler (Bio-Rad Laboratories, Hercules, CA) and
primers listed in Table 2. The cDNA samples were prepared
from fibroblasts originating from two different human donor
corneas. Each PCR was repeated at least three times.
Gene expression quantification by qPCR: The relative
quantification of TGIFs mRNA was performed using the
StepOne Plus real-time PCR system (Applied Biosystems,
Carlsbad, CA). A 20 µl reaction mixture containing 2 µl
of cDNA, 2 µl of forward primer (200 nM), 2 µl of reverse
primer (200 nM), and 10 µl of 2X SYBR green super mix
975
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Table 1. Nucleotide sequences of two validated RNAi and siRNA oligos used in the study.
Smad2 RNAi-1 validated (5′ to 3′)

GAGCAGAACCTCTCTGAATTTGGTTTTGGCCACTGACTGACCAAATTCAGAGGTTCTGCT

Smad2 RNAi-2 validated (5′ to 3′)

GTGTAAAGGCCTGTTGTATCCCGTTTTGGCCACTGACTGACGGGATACAAGGCCTTTACA

Smad3 RNAi-1 validated (5′ to 3′)

GCACTGAGGCACTCTGCGAAGAGTTTTGGCCACTGACTGACTCTTCGCAGTGCCTCAGTG

Smad3 RNAi-2 validated (5′ to 3′)

GTTCATCTGGTGGTCACTGGTTGTTTTGGCCACTGACTGACAACCAGTGCACCAGATGAA

Smad4 RNAi-1 validated (5′ to 3′)

GTATGATGGTAAGTAGCTGGCTGTTTTGGCCACTGACTGACAGCCAGCTTTACCATCATA

Smad4 RNAi-2 validated (5′ to 3′)

GTTTCCGACCAGCCACCTGAAGGTTTTGGCCACTGACTGACCTTCAGGTCTGGTCGGAAA

TGIF1 siRNA-1 validated (5′ to 3′)

GCAUGGACAUUCCCUUGGATT

TGIF1 siRNA-2 validated (5′ to 3′)

GCACCGUUACAAUGCCUAUTT

TGIF2 siRNA-1 validated (5′ to 3′)

GCCUCCUAGCUGGGAUUGUTT

TGIF2 siRNA-2 validated (5′ to 3′)

GGACGACAGCCUUUAGUUUTT

(Bio-Rad Laboratories, Hercules, CA) was run at a universal
cycle (95 °C for 10 min, 40 cycles at 95 °C for 15 s, and 60 °C
for 60 s) in accordance with the manufacturer’s instructions,
using primers listed in Table 2.
Immunoblotting: Both the treated and untreated HCF cultures
were lysed in a radioimmunoprecipitation assay (RIPA) lysis
buffer containing a protease inhibitor cocktail (Santa Cruz
Biotechnology, Santa Cruz, CA) followed by centrifugation
at 10,000 g for 10 min. Samples were suspended in a NuPAGE
LDS buffer containing a reducing agent (Life Technologies
Corporation, Grand Island, NY) and heated at 70 °C for
10 min. Protein samples were resolved by NuPAGE Novex
Bis-Tris mini gels (Invitrogen) and transferred onto the
polyvinylidene difluoride membranes using wet transfer at
25 V. The transferred proteins were detected by incubating
the membrane with primary antibodies: TGIF1, TGIF2 (Santa
Cruz Biotechnology, Santa Cruz, CA), acetylhistone H3,

acetyl histone H4 (EMD Millipore, Billerica, MA), alpha
smooth muscle actin (αSMA Dako, Carpinteria, CA), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Santa
Cruz Biotechnology), followed by alkaline phosphatase
conjugated anti-mouse, anti-goat, or anti-rabbit secondary
antibody. After washing three times in 0.05% Tween-20 in
Tris-buffered saline of pH 8.0 for 5 min each, the blot was
developed using the nitroblue tetrazolium/5-bromo-4-chloro3-indolylphosphate method. Three separate western blots
were performed for each experiment. The digital quantification of western blots was performed using NIH Image J
software.
Immunofluorescence: Cells were fixed with 4% paraformaldehyde, and immunofluorescence staining for α–smooth
muscle actin (1:200 dilution) and acetyl histone H3 (1:100
dilution EMD Millipore, Billerica, MA) was performed.
Samples were incubated with 5% BSA for 30 min at room

Table 2. Sequences of primers used in the study.
Gene

Forward (5′ to 3′)

Reverse (5′ to 3′)

Accession Number

Smooth muscle actin

TGGGTGACGAAGCACAGAGC CTTCAGGGGCAACACGAAGC

NM_001613

TGIF1

CTGTGTTTCGAGGATGGTTC

CATGGAAAGGAATCAGAGCC

NM_170695

TGIF2

CCTGTCAGTGCTGCAAAT

GGCGGGAAATGGTAAACT

NM_021809.5

β-actin

CGGCTACAGCTTCACCACCA

CGGGCAGCTCGTAGCTCTTC

NM_007393.4

TGIF1

GACATTCCCTTGGACCTTTCT GACCACTCTGTGTATTCGTACTT NM_170695

TGIF2

GGCACCTAGCAGAGAAAGATAAG

For Real Time PCR

For PCR
GGGAGGCTGAGGCAAATAAT
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temperature, followed by primary antibody incubation for 90
min. The secondary antibodies Alexa 488 donkey anti-rabbit
and Alexa 594 donkey anti-mouse IgG secondary antibody
(1:500 dilution) were incubated for 1 h. The cells were washed
three times in PBS buffer, mounted in Vectashield containing
4'-6-diamidino-2-phenylindole (DAPI; Vector Laboratories),
and viewed and photographed with a Leica fluorescent microscope (Leica DM 4000B) equipped with a digital camera
(SpotCam RT KE).
Statistical analyses: Results were expressed as a mean ± standard error. Statistical analysis was performed using one-way
ANOVA and Tukey’s test. A value of p<0.05 was considered
significant.
RESULTS
Detection of TGIF1 and TGIF2 in human corneal fibroblasts:
To investigate whether human corneal fibroblasts express
TGIFs, PCR was performed to detect the presence from
mRNA transcripts for TGIF1 and TGIF2. Figure 1 shows
the agarose gel electrophoresis of the PCR demonstrating
the presence of amplified bands for TGIF1 and TGIF2 in the
cDNA obtained from human corneal fibroblasts. An appropriately sized amplification product of 608 bp was detected
for TGIF1 in two cDNA samples of human corneal fibroblasts
originating from two separate donor human corneas. Amplification products for TGIF2 corresponding to the product size
of 646 bp were also present in the human corneal fibroblast
cDNA samples. No PCR product was detected in the negative controls that contained primers for TGIFs but no cDNA
(Figure 1).
Effect of vorinostat on TGIF1 and TGIF2 expression and
histone acetylation: After confirming that human corneal
fibroblasts express TGIF1 and TGIF2, we next tested if

© 2015 Molecular Vision

vorinostat treatment of human corneal fibroblasts increased
TGIF expression. The mRNA and protein lysates were
obtained from the human corneal fibroblasts +/− vorinostat.
As is evident from Figure 2A, treatment of human corneal
fibroblasts with vorinostat (2.5 µM) caused a 2.8±0.81fold increase (p<0.05) in TGIF1 mRNA and 3.3±0.25-fold
increase (p<0.01) in TGIF2 mRNA levels as compared
to DMSO-treated vehicle control groups (–vorinostat).
Figure 2B shows the western blot detection of TGIF protein
levels in DMSO-treated vehicle control and vorinostat
(2.5 µM)-exposed human corneal fibroblasts. The immunoblotting data demonstrated that vorinostat caused a 1.4-fold
increase (p<0.05) in TGIF1 and 1.8-fold increase (p<0.05)
in TGIF2 protein in comparison to vehicle-treated control
human corneal fibroblasts. Further, we also tested the effect
of vorinostat on TGIF1 and TGIF2 expression in corneal
keratocytes. The corneal keratocytes were isolated using
dispase and collagenase enzymatic digestions and grown in
serum-free medium in the presence or absence of vorinostat.
Our results demonstrate that vorinostat increased the TGIF1
and TGIF2 mRNA in human corneal keratocytes as observed
in human corneal fibroblasts (data not shown).
We further postulated that the observed increase in
TGIFs was likely mediated by enhanced transcription due
to histone acetylation and DNA unfolding caused by vorinostat. To test whether the 2.5 µM dose of vorinostat used
in the present study was sufficient to cause histone acetylation, we performed immunoblotting for acetylated histone
H3 and acetylated histone H4. As can be seen in Figure 3A,
vorinostat treatment of human corneal fibroblasts caused
an 8-fold increase (p<0.001) in acetylhistone H3 and a
50-fold increase (p<0.001) in acetylhistone H4. Figure 3B
demonstrated that only 36±4% of nuclei stained +ve for
acetylhistone H3 in DMSO-treated vehicle control corneal

Figure 1. Agarose gel electrophoresis of PCR showing the detection of TGIF1 and TGIF2 mRNA
expression in human cor neal
fibroblasts. Appropriately sized
PCR amplification products for
TGIF1 and TGIF2 were detected
in two independent cDNA samples
(S1 and S2) of corneal fibroblasts
prepared from two separate human
donor corneas. The lower level of
TGIF detected in sample S2 is due
to a smaller amount of starting cDNA in the PCR reaction. -ve denotes negative controls that contained TGIF1 and TGIF2 primers but water
instead of cDNA. L denotes a 100-base-pair DNA ladder.
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Figure 2. Quantitative real-time
PCR and immunoblotting demonstrating the effect of vorinostat (2.5
µM) on TGIF1 and TGIF2 mRNA
and protein levels. A significant
increase in TGIF1 and TGIF2
mRNA (A) and protein (B) levels
is evident after vorinostat treatment (+vorinostat) as compared
to DMSO-treated vehicle controls
(–vorinostat). * p<0.05, # p<0.01
compared to vorinostat.

fibroblasts (–vorinostat). On the other hand, vorinostat treatment of human corneal fibroblasts significantly increased the
acetylhistone H3 to 75±3.4% (p<0.001) nuclei showing +ve
staining. A similar trend demonstrating the increase in acetylhistone H4-stained nuclei was also observed with vorinostat
(data not shown). No statistically significant difference in the
total number of DAPI-stained nuclei (blue) was observed in
the control and vorinostat-exposed human corneal fibroblasts
(Figure 3B).

contractile, metabolically active, and opaque cells containing
intracellular microfilament bundles of αSMA, which serves as
a maker for fibrosis. As expected, TGFβ1treatment of human
corneal fibroblasts caused a 3.8±0.2-fold increase (p<0.001)
in αSMA mRNA (Figure 5A) and a 4.3-fold increase (p<0.01)
in SMA protein (Figure 5B). Vorinostat treatment significantly attenuated TGFβ 1-induced increases in αSMA mRNA
by 83±7.7% (p<0.001, Figure 5A) and protein levels by 97±5%
(p<0.001, Figure 5B).

Effect of Smad knockdown on TGFβ1-induced myofibroblasts
formation: TGIFs are negative regulators of TGFβ1-mediated
Smad signaling. Therefore, we next tested the hypothesis that
TGFβ1-mediated transdifferentiation of human corneal fibroblasts to myofibroblasts is largely mediated through Smad
signaling. To test this hypothesis, we transfected the human
corneal fibroblasts with plasmids expressing Smad2/Smad3
or Smad4 RNAi. Figure 4 shows the effect of RNAi-mediated
knockdown of Smad2/Smad3 or Smad4 on TGFβ1-evoked
SMA formation. As is evident from Figure 4, the knockdown
of Smad2/Smad3 or Smad4 markedly attenuated TGFβ1mediated increase in αSMA in cultured human corneal
fibroblasts tested using immunofluorescence (Figure 4A-E)
and immunoblotting (Figure 4F). This suggests that TGFβ1mediated transdifferentiation of human corneal fibroblasts to
myofibroblasts is largely mediated through Smad signaling.

The antifibrotic effects of vorinostat were further
investigated by αSMA immuno-cytochemistry (Figure 6).
As anticipated, human corneal fibroblasts cultured in the
absence of TGFβ1 (–TGFβ) under serum-free conditions
showed minimal αSMA expression (Figure 6). TGFβ1 (5 ng/
ml) treatment caused a robust myofibroblast formation, as
indicated by an intense αSMA immunostaining in 82%–94%
of cells (p<0.001). Following vorinostat treatment, only
6%–8% of cells (p<0.001) showed αSMA immunostaining,
confirming that vorinostat remarkably attenuates TGFβ1evoked myofibroblast formation (Figure 6).

Effect of vorinostat on myofibroblast formation: Next, we
tested the hypothesis that vorinostat-induced increases
in TGIF1 and TGIF2 were accompanied by a concurrent
decrease in corneal fibrosis. An in vitro model of corneal
fibrosis in which the application of TGFβ1 induces myofibroblasts formation was used to test this hypothesis. The transformation of corneal fibroblasts to myofibroblasts is a key
pathological feature in corneal fibrosis. Myofibroblasts are

Effect of TGIFs knockdown on the antifibrotic effect of
vorinostat: Finally, we tested whether the increase in TGIF
expression is an essential step for the antifibrotic effect of
vorinostat. If so, then the TGIF knockdown should impede
the antifibrotic effect of vorinostat. To test this hypothesis,
we designed a reverse experiment wherein we tested the
antifibrotic effect of vorinostat along with siRNA-mediated
knockdown of TGIFs. Figures 5A and B show that TGIF1 and
TGIF2 knockdown prevented vorinostat-mediated decreases
in αSMA mRNA by 31%–45% (p<0.05) and protein levels by
12%–23% (p<0.05), respectively. Similarly, immunostaining
data for αSMA shows that TGIF1 or TGIF2 siRNA knockdown significantly prevented vorinostat-induced decreases
978
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in myofibroblast formation. Only 6%–8% of cells (p<0.05)
showed αSMA immunostaining when exposed to vorinostat
alone, whereas 12%–18% of cells (p<0.05) stained for αSMA
when cells were exposed to vorinostat after either TGIF1 or
TGIF2 knockdown (Figure 6). Overall, our data suggest that
the knockdown of either TGIF1 or TGIF2 partially blocks the
antifibrotic effect of vorinostat.
To test whether the simultaneous knockdown of both
TGIF1 and TGIF2 had any additive or synergistic effect on
blocking the antifibrotic effect of vorinostat, we treated the
cells with siRNA of both TGIF1 and TGIF2. However, the
simultaneous knockdown of TGIF1 and TGIF2 did not cause
any additive neutralization of vorinostat on αSMA mRNA
(Figure 5A) or protein (Figure 5B and Figure 6) as compared
to the knockdown of either the TGIF1 or TGIF2 alone.

© 2015 Molecular Vision

DISCUSSION
TGIFs belong to the three-amino acid loop extension (TALE)
family of homeodomain proteins consisting of two transcription factors, TGIF1 and its closely related paralog TGIF2.
TGIFs are highly expressed during mammalian embryonic
development and have been shown to play a critical role in
the development of many organs, including the eyes [28-30].
However, after birth, TGIF expression sharply declines, with
only a handful of tissues showing detectable levels of TGIFs
in adult animals [25,27]. In the present study, we demonstrate
that human corneal fibroblasts express both TGIF1 and
TGIF2. A literature survey reveals that very limited information is available concerning the biologic functions of TGIFs in
fully differentiated adult tissues. Therefore, our data open up

Figure 3. Representative immunoblotting and immunof luorescence images showing the effect
of vorinostat (2.5 µM) on histone
acet ylat ion. I m mu noblot t i ng
image and the quantif ication
graph (A) showing that vorinostat
(+vorinostat) caused eight fold and
50 fold (Ψ p<0.001) increase in
acetylhistone H3 and acetylhistone
H4 protein levels in comparison
to DMSO-treated vehicle controls
(–vorinostat). Immunofluorescence
images (B) show significantly
more nuclei (p<0.001) stained +ve
for acetylhistone H3 (Green) in
vorinostat-exposed human corneal
fibroblast cultures (+vorinostat) as
compared to non-treated controls
(–vorinostat). The DAPI-staining
(blue) depicts that there was no
significant difference in the total
number of nuclei between control
and vorinostat-treated cultures.
Scale bar=100 μm.
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Figure 4. Representative immunofluorescence images and immunoblotting showing the effect of RNAi-mediated Smad2/3/4 knockdown
on αSMA. Control human corneal fibroblast cultures (–TGFβ) showed no αSMA staining (A) or protein levels (F). Cultures treated with
TGFβ1 (5 ng/ml) showed robust αSMA staining (B) and protein levels (F). The knockdown of Smad2 (C, F)/Smad3 (D, F)/Smad4 (E, F)
markedly blocked TGFβ-evoked increase in αSMA.

the exciting possibility of investigating the biologic functions
of these transcription factors in the corneal tissue.
HDACs are a group of enzymes that deacetylate histone
and non-histone proteins and are critically involved in the
epigenetic regulation of gene transcription, cellular proliferation, survival, and differentiation [31-33]. Given their critical
role in modulating cell cycles, HDACs have been extensively
studied in cancer biology. In addition, the role of HDACs and

epigenetic modulation has been implicated in many other
diseases, including fibrosis, autoimmune, inflammatory,
and metabolic diseases processes [34-40]. This has led to
the testing of a variety of HDAC inhibitors to treat fibrotic
diseases, inflammatory bowel diseases, multiple sclerosis,
and systemic lupus erythematosus [34-40]. Our laboratory has
recently demonstrated that the HDAC inhibitor trichostatin
A and its FDA-approved derivative, vorinostat, effectively

Figure 5. Quantitative real-time
PCR and immunoblotting showing
the effect of vorinostat (2.5
µM), TGIF1, and TGIF2 siRNA
knockdown on αSMA protein
levels. Control human corneal
fibroblast cultures (–TGFβ) showed
no αSMA expression. Cultures
treated with TGFβ1 (5 ng/ml)
showed robust αSMA increase.
Vorinostat (+TGFβ+vorinostat)
treatment markedly attenuated
TGFβ-evoked αSMA mRNA (A) and protein (B) expression. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone
(+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ+vorinostat+TGIF1+2siRNA) significantly reversed the effect of vorinostat on
αSMA. * p<0.001 compared to –TGFβ, Ψ p<0.001 compared to +TGFβ, # p<0.05 compared to +TGFβ+vorinostat.
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reduce corneal fibrosis primarily through the inhibition of
TGFβ effects [14-17]. Precisely how HDAC inhibitors block
the biologic effects of TGFβ is not known. TGIFs are known
transcriptional repressors of TGFβ-mediated Smad signaling,
and our RNAi data suggest that TGFβ-driven transdifferentiation of human corneal fibroblasts to myofibroblasts is largely
mediated through Smad signaling. TGIFs have been shown
to directly associate with Smad2/3 and inhibit TGFβ-driven
profibrotic gene expression [23]. Therefore, we postulated
that HDAC inhibitors attenuate corneal fibrosis by increasing
TGIFs. Indeed, the detection of significantly increased levels
of TGIF mRNA and protein in vorinostat-treated human
corneal fibroblasts not only supports our hypothesis but also
provides the evidence that TGIF levels can be potentially
altered in the adult human cornea through pharmacological
manipulation. Furthermore, vorinostat-induced increases
in TGIFs were concurrently accompanied by a remarkable
increase in the acetylation of histones H3 and H4, which is a
well-known effect of HDAC inhibitors. Histone acetylation
increases DNA transcriptional activity, and may explain the

© 2015 Molecular Vision

increased transcriptional levels of TGIFs in human corneal
fibroblasts following vorinostat treatment. Next, we reasoned
that, if increased TGIF expression is an essential step for the
antifibrotic effect of vorinostat, then the drug should lose
its antifibrotic effect without TGIFs. To test this hypothesis,
we used siRNAs to knockdown TGIFs. We observed that
vorinostat showed a significantly diminished antifibrotic
effect, as indicated by increased αSMA when either TGIF1
or TGIF2 was knocked down. These results suggest that
TGIFs are vital for the antifibrotic effect of vorinostat in the
cornea. However, it is worthwhile to point out that only a
partial reversal of the antifibrotic effect of vorinostat was
achieved by knocking down the TGIFs. Multiple factors can
account for this observed partial reversal. TGIFs are shortlived proteins and undergo rapid synthesis and degradation
[41]. Therefore, the noted partial reversal of vorinostat effects
could be due to the quick de novo synthesis of TGIFs that
can partially counterbalance the siRNA knockdown. Alternatively, vorinostat may have caused a concurrent increase
in the transcription levels of other know TGFβ co-repressors,

Figure 6. Representative immunofluorescence images and the quantification graph showing the effect
of vorinostat (2.5 µM), TGIF1,
and TGIF2 siRNA knockdown on
αSMA. Control human corneal
fibroblast cultures (-TGFβ) showed
no αSM A staining. Cult ures
treated with TGFβ1 (5 ng/ml)
showed a robust αSMA staining.
Vorinostat treatment markedly
attenuated TGFβ-evoked αSMA
staining. The knockdown of TGIF1
(+TGFβ+vorinostat+TGIF1siRNA)
and
TGIF2
alone
(+TGFβ+vorinostat+TGIF2siRNA)
or i n c ombi n at ion (+TGFβ
+vorinostat +TGIF1 +2siRNA)
markedly blocked the effect
of vorinostat on αSMA. Scale
bar=100 μm. * p<0.001 compared
to –TGFβ, Ψ p<0.001 compared
to +TGFβ, # p<0.05 compared to
+TGFβ+vorinostat.
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Figure 7. Schematic representation
of the role of TGIFs in the antifibrotic effect of vorinostat in the
cornea.

such as c-Ski, SnoN, Smad6, and Smad7 [18-20], and in that
case, the selective knockdown of only TGIFs will merely
partially reverse the antifibrotic effects of vorinostat. Future
studies will test the role of other TGFβ co-repressors in
modulating the antifibrotic effect of vorinostat.

4.

Wilson SE, Liu JJ, Mohan RR. Stromal-epithelial interactions
in the cornea. Prog Retin Eye Res 1999; 18:293-309. [PMID:
10192515].

5.

In conclusion, we demonstrate that human corneal fibroblasts express TGIF1 and TGIF2 transcription factors. These
transcriptional repressors are critical, at least partially, in
mediating the antifibrotic effect of vorinostat in the cornea
(Figure 7).

Saika S, Yamanaka O, Sumioka T, Okada Y, Miyamoto T,
Shirai K, Kitano A, Tanaka S. Transforming growth factor
beta signal transduction: a potential target for maintenance /
restoration of transparency of the cornea. Eye Contact Lens
2010; 36:286-9. [PMID: 20823707].

6.
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transforming growth factor Beta in corneal function, biology
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20642439].

ACKNOWLEDGMENTS

7.

The work was supported from the Veteran Health Affairs
Merit 1I01BX000357 grant (RRM), and partially from the
National Eye Institute RO1EY017294 grant (RRM) and the
University of Missouri Ruth M. Kraeuchi Missouri Ophthalmology Endowment Fund (RRM).

Hutcheon AE, Guo XQ, Stepp MA, Simon KJ, Weinreb PH,
Violette SM, Zieske JD. Effect of wound type on Smad 2 and
4 translocation. Invest Ophthalmol Vis Sci 2005; 46:2362-8.
[PMID: 15980223].

8.

Kitano A, Okada Y, Yamanka O, Shirai K, Mohan RR, Saika
S. Therapeutic potential of trichostatin A to control inflammatory and fibrogenic disorders of the ocular surface. Mol
Vis 2010; 16:2964-73. [PMID: 21203344].

9.

Wang L, Ko CY, Meyers EE, Pedroja BS, Pelaez N, Bernstein
AM. Concentration-dependent effects of transforming
growth factor β1 on corneal wound healing. Mol Vis 2011;
17:2835-46. [PMID: 22128231].

REFERENCES
1.

Foster A, Resnikoff S. The impact of Vision 2020 on global
blindness. Eye (Lond) 2005; 19:1133-5. [PMID: 16304595].

2.

Yu FS, Yin J, Xu K, Huang J. Growth factors and corneal
epithelial wound healing. Brain Res Bull 2010; 81:229-35.
[PMID: 19733636].

3.

Wilson SE, Mohan RR, Mohan RR, Ambrósio R Jr, Hong
J, Lee J. The corneal wound healing response: cytokinemediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res 2001; 20:625-37. [PMID:
11470453].

10. Rombouts K, Niki T, Greenwel P, Vandermonde A, Wielant A,
Hellemans K, De Bleser P, Yoshida M, Schuppan D, Rojkind
M, Geerts A. Trichostatin A, a histone deacetylase inhibitor,
suppresses collagen synthesis and prevents TGF- 1-induced
fibrogenesis in skin fibroblasts. Exp Cell Res 2002; 278:18497. [PMID: 12169274].
11. Glenisson W, Castronovo V, Waltregny D. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic

982

Molecular Vision 2015; 21:974-984 <http://www.molvis.org/molvis/v21/974>

differentiation. Biochim Biophys Acta 2007; 773:1572-82.
[PMID: 17610967].
12. Liu N, He S, Ma L, Ponnusamy M, Tang J, Tolbert E, Bayliss
G, Zhao TC, Yan H, Zhuang S. Blocking the class I histone
deacetylase ameliorates renal fibrosis and inhibits renal
fibroblast activation via modulating TGF-beta and EGFR
signaling. PLoS ONE 2013; 8:e54001-[PMID: 23342059].
13. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition
of histone deacetylase activity suppresses epithelial-tomesenchymal transition induced by TGF-beta1 in human
renal epithelial cells. J Am Soc Nephrol 2007; 18:58-65.
[PMID: 17135397].
14. Sharma A, Mehan MM, Sinha S, Cowden JW, Mohan RR.
Trichostatin A inhibits corneal haze in vitro and in vivo.
Invest Ophthalmol Vis Sci 2009; 50:2695-701. [PMID:
19168895].
15. Tandon A, Tovey JC, Waggoner MR, Sharma A, Cowden JW,
Gibson DJ, Liu Y, Schultz GS, Mohan RR. Vorinostat: a
potent agent to prevent and treat laser-induced corneal haze.
J Refract Surg 2012; 28:285-90. [PMID: 22386369].
16. Bosiack AP, Giuliano EA, Gupta R, Mohan RR. Efficacy and
safety of suberoylanilide hydroxamic acid (Vorinostat) in the
treatment of canine corneal fibrosis. Vet Ophthalmol 2012;
15:307-14. [PMID: 22212187].
17. Donnelly KS, Giuliano EA, Sharma A, Mohan RR. Suberoylanilide hydroxamic acid (vorinostat): its role on equine
corneal fibrosis and matrix metalloproteinase activity. Vet
Ophthalmol 2014; 17:Suppl 161-8. [PMID: 25126665].
18. Itoh S, ten Dijke P. Negative regulation of TGF-beta receptor/
Smad signal transduction. Curr Opin Cell Biol 2007; 19:17684. [PMID: 17317136].
19. Deheuninck J, Luo K. Ski and SnoN, potent negative regulators
of TGF-beta signaling. Cell Res 2009; 19:47-57. [PMID:
19114989].
20. Yan X, Chen YG. Smad7: not only a regulator, but also a crosstalk mediator of TGF-β signaling. Biochem J 2011; 434:1-10.
[PMID: 21269274].
21. Mar L, Hoodless PA. Embryonic fibroblasts from mice lacking
TGIF were defective in cell cycling. Mol Cell Biol 2006;
26:4302-10. [PMID: 16705179].
22. Hamid R, Brandt SJ. Transforming growth-interacting factor
(TGIF) regulates proliferation and differentiation of human
myeloid leukemia cells. Mol Oncol 2009; 3:451-63. [PMID:
19699159].

© 2015 Molecular Vision

25. Bertolino E, Reimund B, Wildt-Perinic D, Clerc RG. A novel
homeobox protein which recognizes a TGT core and functionally interferes with a retinoid-responsive motif. J Biol
Chem 1995; 270:31178-88. [PMID: 8537382].
26. Scavello GS, Paluru PC, Ganter WR, Young TL. Sequence
variants in the transforming growth beta-induced factor
(TGIF) gene are not associated with high myopia. Invest
Ophthalmol Vis Sci 2004; 45:2091-7. [PMID: 15223781].
27. Imoto I, Pimkhaokham A, Watanabe T, Saito-Ohara F, Soeda
E, Inazawa J. Amplification and overexpression of TGIF2,
a novel homeobox gene of the TALE superclass, in ovarian
cancer cell lines. Biochem Biophys Res Commun 2000;
276:264-70. [PMID: 11006116].
28. Powers SE, Taniguchi K, Yen W, Melhuish TA, Shen J, Walsh
CA, Sutherland AE, Wotton D. TGIF1 and TGIF2 regulate
Nodal signaling and are required for gastrulation. Development 2010; 137:249-59. [PMID: 20040491].
29. Bartholin L, Melhuish TA, Powers SE, Goddard-Léon S, Treilleux I, Sutherland AE, Wotton D. Maternal TGIF is required
for vascularization of the embryonic placenta. Dev Biol
2008; 319:285-97. [PMID: 18508043].
30. Satoh S, Watanabe S. TGIF, a homeodomain transcription
factor, regulates retinal progenitor cell differentiation. Exp
Eye Res 2008; 87:571-9. [PMID: 18926818].
31. Jaenisch R, Bird A. Epigenetic regulation of gene expression:
how the genome integrates intrinsic and environmental
signals. Nat Genet 2003; 33:Suppl245-54. [PMID: 12610534].
32. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkühler C.
HDACs, histone deacetylation and gene transcription: from
molecular biology to cancer therapeutics. Cell Res 2007;
17:195-211. [PMID: 17325692].
33. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam
A, Ponte JF. Histone deacetylases: unique players in shaping
the epigenetic histone code. Ann N Y Acad Sci 2003;
983:84-100. [PMID: 12724214].
34. Pang M, Zhuang S. Histone deacetylase: a potential therapeutic
target for fibrotic disorders. J Pharmacol Exp Ther 2010;
335:266-72. [PMID: 20719940].
35. Van Beneden K, Mannaerts I, Pauwels M, Van den Branden
C, van Grunsven LA. HDAC inhibitors in experimental
liver and kidney fibrosis. Fibrogenesis Tissue Repair. 2013;
6:1-[PMID: 23281659].

23. Wotton D, Lo RS, Swaby LA, Massagué J. Multiple modes of
repression by the Smad transcriptional corepressor TGIF. J
Biol Chem 1999; 274:37105-10. [PMID: 10601270].

36. Wang Z, Chen C, Finger SN, Kwajah S, Jung M, Schwarz
H, Swanson N, Lareu FF, Raghunath M. Suberoylanilide
hydroxamic acid: a potential epigenetic therapeutic agent
for lung fibrosis? Eur Respir J 2009; 34:145-55. [PMID:
19224893].

24. Gripp KW, Wotton D, Edwards MC, Roessler E, Ades L,
Meinecke P, Richieri-Costa A, Zackai EH, Massagué J,
Muenke M, Elledge SJ. Mutations in TGIF cause holoprosencephaly and link NODAL signaling to human neural
axis determination. Nat Genet 2000; 25:205-8. [PMID:
10835638].

38. Tang J, Yan H, Zhuang S. Histone deacetylases as targets
for treatment of multiple diseases. Clin Sci (Lond) 2013;
124:651-62. [PMID: 23414309].

37. Tao H, Shi KH, Yang JJ, Huang C, Zhan HY, Li J. Histone
deacetylases in cardiac fibrosis: current perspectives for
therapy. Cell Signal 2014; 26:521-7. [PMID: 24321371].

983

Molecular Vision 2015; 21:974-984 <http://www.molvis.org/molvis/v21/974>

39. Vojinovic J, Damjanov N. HDAC inhibition in rheumatoid
arthritis and juvenile idiopathic arthritis. Mol Med 2011;
17:397-403. [PMID: 21308151].
40. Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br
J Pharmacol 2007; 150:829-31. [PMID: 17325655].

© 2015 Molecular Vision

41. Lo RS, Wotton D, Massagué J. Epidermal growth factor
signaling via Ras controls the Smad transcriptional
co-repressor TGIF. EMBO J 2001; 20:128-36. [PMID:
11226163].

Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China.
The print version of this article was created on 28 August 2015. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
984

